APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Receptor Agonist

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Opioid Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025198 pages

Choose your research edition.

Industry ResearchOpioid Receptor Agonist Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Receptor Agonist Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Opioid Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Receptor Agonist Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Receptor Agonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Opioid Receptor Agonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Opioid Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Opioid Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Opioid Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Opioid Receptor Agonist include Allergan, DAIICHI SANKYO COMPANY, Endo Pharmaceuticals, Fresenius Kabi, Hikma Pharmaceuticals, Indivior, Mylan N.V., Piramal Critical Care and Purdue Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Opioid Receptor Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid Receptor Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid Receptor Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid Receptor Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioid Receptor Agonist Segment by Company

Allergan

DAIICHI SANKYO COMPANY

Endo Pharmaceuticals

Fresenius Kabi

Hikma Pharmaceuticals

Indivior

Mylan N.V.

Piramal Critical Care

Purdue Pharma

Sun Pharmaceutical Industries

Tris Pharma

US WorldMeds

Pfizer

Johnson & Johnson

Teva Pharmaceutical Industries

Opioid Receptor Agonist Segment by Type

Morphine

Codeine

Fentanyl

Others

Opioid Receptor Agonist Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Opioid Receptor Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Receptor Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid Receptor Agonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Opioid Receptor Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Opioid Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Opioid Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Opioid Receptor Agonist Industry Trends Table 2. Opioid Receptor Agonist Industry Drivers Table 3. Opioid Receptor Agonist Industry Opportunities and Challenges Table 4. Opioid Receptor Agonist Industry Restraints Table 5. Global Opioid Receptor Agonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Opioid Receptor Agonist Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Opioid Receptor Agonist Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Opioid Receptor Agonist Sales Market Share by Manufacturers Table 9. Global Opioid Receptor Agonist Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Opioid Receptor Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Opioid Receptor Agonist Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Opioid Receptor Agonist Manufacturers, Product Type & Application Table 13. Global Opioid Receptor Agonist Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioid Receptor Agonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Morphine Table 17. Major Manufacturers of Codeine Table 18. Major Manufacturers of Fentanyl Table 19. Major Manufacturers of Others Table 20. Global Opioid Receptor Agonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Opioid Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 22. Global Opioid Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 23. Global Opioid Receptor Agonist Sales Market Share by Type (2021-2026) Table 24. Global Opioid Receptor Agonist Sales Market Share by Type (2027-2032) Table 25. Global Opioid Receptor Agonist Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Opioid Receptor Agonist Revenue by Type (2021-2026) & (K Units) Table 27. Global Opioid Receptor Agonist Revenue by Type (2027-2032) & (K Units) Table 28. Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2026) Table 29. Global Opioid Receptor Agonist Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Retail Pharmacy Table 31. Major Manufacturers of Online Pharmacy Table 32. Major Manufacturers of Hospital Pharmacy Table 33. Global Opioid Receptor Agonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Opioid Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 35. Global Opioid Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 36. Global Opioid Receptor Agonist Sales Market Share by Application (2021-2026) Table 37. Global Opioid Receptor Agonist Sales Market Share by Application (2027-2032) Table 38. Global Opioid Receptor Agonist Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Opioid Receptor Agonist Revenue by Application (2021-2026) & (K Units) Table 40. Global Opioid Receptor Agonist Revenue by Application (2027-2032) & (K Units) Table 41. Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2026) Table 42. Global Opioid Receptor Agonist Revenue Market Share by Application (2027-2032) Table 43. Global Opioid Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Opioid Receptor Agonist Sales by Region (2021-2026) & (K Units) Table 45. Global Opioid Receptor Agonist Sales Market Share by Region (2021-2026) Table 46. Global Opioid Receptor Agonist Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Opioid Receptor Agonist Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Opioid Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 50. North America Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 51. Europe Opioid Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 53. Europe Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Opioid Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Opioid Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 60. Global Opioid Receptor Agonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Opioid Receptor Agonist Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Opioid Receptor Agonist Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Opioid Receptor Agonist Revenue Market Share by Region (2021-2026) Table 64. Global Opioid Receptor Agonist Revenue Market Share by Region (2027-2032) Table 65. Allergan Company Information Table 66. Allergan Business Overview Table 67. Allergan Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Allergan Opioid Receptor Agonist Product Portfolio Table 69. Allergan Recent Development Table 70. DAIICHI SANKYO COMPANY Company Information Table 71. DAIICHI SANKYO COMPANY Business Overview Table 72. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio Table 74. DAIICHI SANKYO COMPANY Recent Development Table 75. Endo Pharmaceuticals Company Information Table 76. Endo Pharmaceuticals Business Overview Table 77. Endo Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio Table 79. Endo Pharmaceuticals Recent Development Table 80. Fresenius Kabi Company Information Table 81. Fresenius Kabi Business Overview Table 82. Fresenius Kabi Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Fresenius Kabi Opioid Receptor Agonist Product Portfolio Table 84. Fresenius Kabi Recent Development Table 85. Hikma Pharmaceuticals Company Information Table 86. Hikma Pharmaceuticals Business Overview Table 87. Hikma Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio Table 89. Hikma Pharmaceuticals Recent Development Table 90. Indivior Company Information Table 91. Indivior Business Overview Table 92. Indivior Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Indivior Opioid Receptor Agonist Product Portfolio Table 94. Indivior Recent Development Table 95. Mylan N.V. Company Information Table 96. Mylan N.V. Business Overview Table 97. Mylan N.V. Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Mylan N.V. Opioid Receptor Agonist Product Portfolio Table 99. Mylan N.V. Recent Development Table 100. Piramal Critical Care Company Information Table 101. Piramal Critical Care Business Overview Table 102. Piramal Critical Care Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Piramal Critical Care Opioid Receptor Agonist Product Portfolio Table 104. Piramal Critical Care Recent Development Table 105. Purdue Pharma Company Information Table 106. Purdue Pharma Business Overview Table 107. Purdue Pharma Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Purdue Pharma Opioid Receptor Agonist Product Portfolio Table 109. Purdue Pharma Recent Development Table 110. Sun Pharmaceutical Industries Company Information Table 111. Sun Pharmaceutical Industries Business Overview Table 112. Sun Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio Table 114. Sun Pharmaceutical Industries Recent Development Table 115. Tris Pharma Company Information Table 116. Tris Pharma Business Overview Table 117. Tris Pharma Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Tris Pharma Opioid Receptor Agonist Product Portfolio Table 119. Tris Pharma Recent Development Table 120. US WorldMeds Company Information Table 121. US WorldMeds Business Overview Table 122. US WorldMeds Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. US WorldMeds Opioid Receptor Agonist Product Portfolio Table 124. US WorldMeds Recent Development Table 125. Pfizer Company Information Table 126. Pfizer Business Overview Table 127. Pfizer Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Pfizer Opioid Receptor Agonist Product Portfolio Table 129. Pfizer Recent Development Table 130. Johnson & Johnson Company Information Table 131. Johnson & Johnson Business Overview Table 132. Johnson & Johnson Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Johnson & Johnson Opioid Receptor Agonist Product Portfolio Table 134. Johnson & Johnson Recent Development Table 135. Teva Pharmaceutical Industries Company Information Table 136. Teva Pharmaceutical Industries Business Overview Table 137. Teva Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio Table 139. Teva Pharmaceutical Industries Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Opioid Receptor Agonist Distributors List Table 143. Opioid Receptor Agonist Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Opioid Receptor Agonist Product Image Figure 2. Global Opioid Receptor Agonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Receptor Agonist Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioid Receptor Agonist Sales (2021-2032) & (K Units) Figure 5. Global Opioid Receptor Agonist Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Opioid Receptor Agonist Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Morphine Image Figure 9. Codeine Image Figure 10. Fentanyl Image Figure 11. Others Image Figure 12. Global Opioid Receptor Agonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Opioid Receptor Agonist Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Opioid Receptor Agonist Sales Market Share by Type (2021-2032) Figure 15. Global Opioid Receptor Agonist Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Opioid Receptor Agonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2032) Figure 18. Retail Pharmacy Image Figure 19. Online Pharmacy Image Figure 20. Hospital Pharmacy Image Figure 21. Global Opioid Receptor Agonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Opioid Receptor Agonist Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Opioid Receptor Agonist Sales Market Share by Application (2021-2032) Figure 24. Global Opioid Receptor Agonist Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Opioid Receptor Agonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2032) Figure 27. North America Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 29. U.S. Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 34. Germany Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 41. China Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 49. Brazil Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Opioid Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Opioid Receptor Agonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Opioid Receptor Agonist Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 60. North America Opioid Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 62. Europe Opioid Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Opioid Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Opioid Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Opioid Receptor Agonist Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Opioid Receptor Agonist Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Morphine
  • Codeine
  • Fentanyl
  • Others
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Allergan
  • DAIICHI SANKYO COMPANY
  • Endo Pharmaceuticals
  • Fresenius Kabi
  • Hikma Pharmaceuticals
  • Indivior
  • Mylan N.V.
  • Piramal Critical Care
  • Purdue Pharma
  • Sun Pharmaceutical Industries
  • Tris Pharma
  • US WorldMeds
  • Pfizer
  • Johnson & Johnson
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Opioid Receptor Agonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Opioid Receptor Agonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Opioid Receptor Agonist Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Opioid Receptor Agonist Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Opioid Receptor Agonist Market Dynamics
  1. 2.1 Opioid Receptor Agonist Industry Trends
  2. 2.2 Opioid Receptor Agonist Industry Drivers
  3. 2.3 Opioid Receptor Agonist Industry Opportunities and Challenges
  4. 2.4 Opioid Receptor Agonist Industry Restraints
3 Opioid Receptor Agonist Market by Manufacturers
  1. 3.1 Global Opioid Receptor Agonist Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Opioid Receptor Agonist Sales by Manufacturers (2021-2026)
  3. 3.3 Global Opioid Receptor Agonist Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Opioid Receptor Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Opioid Receptor Agonist Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Opioid Receptor Agonist Manufacturers, Product Type & Application
  7. 3.7 Global Opioid Receptor Agonist Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Opioid Receptor Agonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Opioid Receptor Agonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Opioid Receptor Agonist Tier 1, Tier 2, and Tier 3
4 Opioid Receptor Agonist Market by Type
  1. 4.1 Opioid Receptor Agonist Type Introduction
  2. 4.1.1 Morphine
  3. 4.1.2 Codeine
  4. 4.1.3 Fentanyl
  5. 4.1.4 Others
  6. 4.2 Global Opioid Receptor Agonist Sales by Type
  7. 4.2.1 Global Opioid Receptor Agonist Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Opioid Receptor Agonist Sales by Type (2021-2032)
  9. 4.2.3 Global Opioid Receptor Agonist Sales Market Share by Type (2021-2032)
  10. 4.3 Global Opioid Receptor Agonist Revenue by Type
  11. 4.3.1 Global Opioid Receptor Agonist Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Opioid Receptor Agonist Revenue by Type (2021-2032)
  13. 4.3.3 Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2032)
5 Opioid Receptor Agonist Market by Application
  1. 5.1 Opioid Receptor Agonist Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.2 Global Opioid Receptor Agonist Sales by Application
  6. 5.2.1 Global Opioid Receptor Agonist Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid Receptor Agonist Sales by Application (2021-2032)
  8. 5.2.3 Global Opioid Receptor Agonist Sales Market Share by Application (2021-2032)
  9. 5.3 Global Opioid Receptor Agonist Revenue by Application
  10. 5.3.1 Global Opioid Receptor Agonist Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioid Receptor Agonist Revenue by Application (2021-2032)
  12. 5.3.3 Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2032)
6 Global Opioid Receptor Agonist Sales by Region
  1. 6.1 Global Opioid Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid Receptor Agonist Sales by Region (2021-2032)
  3. 6.2.1 Global Opioid Receptor Agonist Sales by Region (2021-2026)
  4. 6.2.2 Global Opioid Receptor Agonist Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Opioid Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Opioid Receptor Agonist Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Opioid Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Opioid Receptor Agonist Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Opioid Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Opioid Receptor Agonist Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Opioid Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Opioid Receptor Agonist Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Opioid Receptor Agonist Revenue by Region
  1. 7.1 Global Opioid Receptor Agonist Revenue by Region
  2. 7.1.1 Global Opioid Receptor Agonist Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Opioid Receptor Agonist Revenue by Region (2021-2026)
  4. 7.1.3 Global Opioid Receptor Agonist Revenue by Region (2027-2032)
  5. 7.1.4 Global Opioid Receptor Agonist Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Opioid Receptor Agonist Revenue (2021-2032)
  8. 7.2.2 North America Opioid Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Opioid Receptor Agonist Revenue (2021-2032)
  11. 7.3.2 Europe Opioid Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Opioid Receptor Agonist Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Opioid Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Opioid Receptor Agonist Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Opioid Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Opioid Receptor Agonist Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 DAIICHI SANKYO COMPANY
  8. 8.2.1 DAIICHI SANKYO COMPANY Company Information
  9. 8.2.2 DAIICHI SANKYO COMPANY Business Overview
  10. 8.2.3 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio
  12. 8.2.5 DAIICHI SANKYO COMPANY Recent Developments
  13. 8.3 Endo Pharmaceuticals
  14. 8.3.1 Endo Pharmaceuticals Company Information
  15. 8.3.2 Endo Pharmaceuticals Business Overview
  16. 8.3.3 Endo Pharmaceuticals Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio
  18. 8.3.5 Endo Pharmaceuticals Recent Developments
  19. 8.4 Fresenius Kabi
  20. 8.4.1 Fresenius Kabi Company Information
  21. 8.4.2 Fresenius Kabi Business Overview
  22. 8.4.3 Fresenius Kabi Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Fresenius Kabi Opioid Receptor Agonist Product Portfolio
  24. 8.4.5 Fresenius Kabi Recent Developments
  25. 8.5 Hikma Pharmaceuticals
  26. 8.5.1 Hikma Pharmaceuticals Company Information
  27. 8.5.2 Hikma Pharmaceuticals Business Overview
  28. 8.5.3 Hikma Pharmaceuticals Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio
  30. 8.5.5 Hikma Pharmaceuticals Recent Developments
  31. 8.6 Indivior
  32. 8.6.1 Indivior Company Information
  33. 8.6.2 Indivior Business Overview
  34. 8.6.3 Indivior Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Indivior Opioid Receptor Agonist Product Portfolio
  36. 8.6.5 Indivior Recent Developments
  37. 8.7 Mylan N.V.
  38. 8.7.1 Mylan N.V. Company Information
  39. 8.7.2 Mylan N.V. Business Overview
  40. 8.7.3 Mylan N.V. Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mylan N.V. Opioid Receptor Agonist Product Portfolio
  42. 8.7.5 Mylan N.V. Recent Developments
  43. 8.8 Piramal Critical Care
  44. 8.8.1 Piramal Critical Care Company Information
  45. 8.8.2 Piramal Critical Care Business Overview
  46. 8.8.3 Piramal Critical Care Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Piramal Critical Care Opioid Receptor Agonist Product Portfolio
  48. 8.8.5 Piramal Critical Care Recent Developments
  49. 8.9 Purdue Pharma
  50. 8.9.1 Purdue Pharma Company Information
  51. 8.9.2 Purdue Pharma Business Overview
  52. 8.9.3 Purdue Pharma Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Purdue Pharma Opioid Receptor Agonist Product Portfolio
  54. 8.9.5 Purdue Pharma Recent Developments
  55. 8.10 Sun Pharmaceutical Industries
  56. 8.10.1 Sun Pharmaceutical Industries Company Information
  57. 8.10.2 Sun Pharmaceutical Industries Business Overview
  58. 8.10.3 Sun Pharmaceutical Industries Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
  60. 8.10.5 Sun Pharmaceutical Industries Recent Developments
  61. 8.11 Tris Pharma
  62. 8.11.1 Tris Pharma Company Information
  63. 8.11.2 Tris Pharma Business Overview
  64. 8.11.3 Tris Pharma Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Tris Pharma Opioid Receptor Agonist Product Portfolio
  66. 8.11.5 Tris Pharma Recent Developments
  67. 8.12 US WorldMeds
  68. 8.12.1 US WorldMeds Company Information
  69. 8.12.2 US WorldMeds Business Overview
  70. 8.12.3 US WorldMeds Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 US WorldMeds Opioid Receptor Agonist Product Portfolio
  72. 8.12.5 US WorldMeds Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Opioid Receptor Agonist Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Johnson & Johnson
  80. 8.14.1 Johnson & Johnson Company Information
  81. 8.14.2 Johnson & Johnson Business Overview
  82. 8.14.3 Johnson & Johnson Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Johnson & Johnson Opioid Receptor Agonist Product Portfolio
  84. 8.14.5 Johnson & Johnson Recent Developments
  85. 8.15 Teva Pharmaceutical Industries
  86. 8.15.1 Teva Pharmaceutical Industries Company Information
  87. 8.15.2 Teva Pharmaceutical Industries Business Overview
  88. 8.15.3 Teva Pharmaceutical Industries Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
  90. 8.15.5 Teva Pharmaceutical Industries Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioid Receptor Agonist Value Chain Analysis
  2. 9.1.1 Opioid Receptor Agonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioid Receptor Agonist Production Mode & Process
  6. 9.2 Opioid Receptor Agonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioid Receptor Agonist Distributors
  9. 9.2.3 Opioid Receptor Agonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst